Autopsy report · NCT03878719

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

“The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Melanoma

Interventions

binimetinib; encorafenib

Participants

1

Sites

1

Countries

Italy

Trials that died the same way

• Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely
  “The trial was prematurely terminated. Termination was not because of safety concerns but due to slow recruitment.” (82% match in meaning)
• A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
  “The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.” (82% match in meaning)
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
  “The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns.” (81% match in meaning)
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
  “Trial terminated due to business decision, not based on any safety or efficacy concerns.” (80% match in meaning)
• Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
  “The trial is terminated due to the extremely low recruitment rate.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.